Development of a Scalable, Racemic First-Generation Route for CXCR7 Antagonist ACT-1004-1239 via <i>cis</i>-to-<i>trans</i> Epimerization and Subsequent Separation of Enantiomers-Reference-Cited by-同舟云学术

Development of a Scalable, Racemic First-Generation Route for CXCR7 Antagonist ACT-1004-1239 via cis-to-trans Epimerization and Subsequent Separation of Enantiomers

Published:2024-01-22 Issue:6 Volume:28 Page:2090-2102
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Schäfer Gabriel¹^ORCID,Fleischer Tony¹,Ahmetovic Muhamed¹,Guerry Philippe¹,Abele Stefan¹

Affiliation:

1. Chemistry Process R&D, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.3c00445

Reference26 articles.

1. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

2. Pattern of CXCR7 Gene Expression in Mouse Brain Under Normal and Inflammatory Conditions

3. CXCR7 Functions as a Scavenger for CXCL12 and CXCL11

4. Cxcr7 Controls Neuronal Migration by Regulating Chemokine Responsiveness

5. Advances in CXCR7 Modulators

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sustainable Manufacturing of trans-4-Trifluoromethyl-l-proline via Stereochemical Editing: A Combined In Silico and Experimental Approach;Organic Process Research & Development;2024-07-31

2. Development of a Scalable, Stereoselective Second-Generation Route for CXCR7 Antagonist ACT-1004-1239 via Chiral Enamine Reduction and a Novel Telescoped Sequence of Transesterification, cis-to-trans Epimerization, and Saponification;Organic Process Research & Development;2024-01-22